Biogen is making a significant move to diversify its product pipeline by acquiring Human Immunology Biosciences (HI-Bio), a startup specializing in immunology drugs. The deal involves an upfront payment of $1.15 billion in cash, with the possibility of an additional $650 million if HI-Bio's lead drug, felzartamab, achieves certain milestones. Felzartamab has successfully completed Phase 2 trials for two kidney conditions and is currently undergoing a third study for IgA nephropathy. The acquisition is expected to close in the third quarter and will not impact Biogen's 2024 financial guidance.
This strategic acquisition is seen as a step towards reducing the overall risk of Biogen's pipeline, which has been heavily focused on neurology. Analysts have praised the move, noting felzartamab's potential as a versatile pipeline agent with promising early results and plans for Phase 3 research. The acquisition aligns with CEO Chris Viehbacher's vision to expand Biogen's presence beyond neurology, following previous efforts to revitalize the company's growth through new leadership and investments in rare disease treatments.
HI-Bio, incubated by Arch Venture Partners and Monograph Capital, has licensed felzartamab and another drug, HIB210, from MorphoSys, which is being acquired by Novartis. HIB210 is currently in Phase 1 testing and shows potential for treating a range of immune-mediated diseases. Felzartamab's progress in Phase 2 studies for primary membranous nephropathy and antibody-mediated rejection in kidney transplant patients, along with the ongoing IgA nephropathy study, positions it as a key asset in Biogen's expanded immunology portfolio.
